Our data show that both MITF-high and MITF-low BRAF-mutant melanoma cells can acquire MAPKi resistance (Fig S7A and B) and that their response to DUSP4 depletion remains unchanged (Fig 5C and F) despite changes in MITF levels during the acquisition of drug resistance. This evidence concerns the gene BRAF and melanoma.